KBC Group NV Acquires 16,375 Shares of Zoetis Inc. $ZTS

KBC Group NV increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 4.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 361,278 shares of the company’s stock after purchasing an additional 16,375 shares during the period. KBC Group NV owned approximately 0.09% of Zoetis worth $25,962,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Zoetis by 12.9% during the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after acquiring an additional 5,474,210 shares in the last quarter. J. Stern & Co. LLP raised its holdings in shares of Zoetis by 12,431.2% during the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after purchasing an additional 23,877,416 shares during the period. State Street Corp raised its holdings in shares of Zoetis by 0.8% during the fourth quarter. State Street Corp now owns 19,796,891 shares of the company’s stock valued at $2,490,845,000 after purchasing an additional 149,382 shares during the period. Geode Capital Management LLC boosted its position in shares of Zoetis by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock worth $1,420,294,000 after purchasing an additional 189,235 shares in the last quarter. Finally, Norges Bank bought a new stake in Zoetis in the 4th quarter valued at about $734,425,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of research reports. BNP Paribas Exane reduced their price objective on Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a research note on Tuesday, August 11th. Piper Sandler reduced their price target on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research report on Monday, August 10th. Barclays lowered their price objective on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 1st. Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, TD Cowen decreased their target price on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a research report on Tuesday, June 30th. Eight equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Zoetis currently has an average rating of “Hold” and an average target price of $109.62.

Zoetis Price Performance

ZTS opened at $73.64 on Friday. Zoetis Inc. has a 1 year low of $71.45 and a 1 year high of $160.48. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The company has a market capitalization of $30.43 billion, a price-to-earnings ratio of 12.13, a P/E/G ratio of 1.28 and a beta of 0.74. The firm’s fifty day moving average price is $76.30 and its two-hundred day moving average price is $99.01.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same quarter in the prior year, the company posted $1.76 earnings per share. The firm’s revenue for the quarter was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, analysts anticipate that Zoetis Inc. will post 6.19 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be paid a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.9%. Zoetis’s dividend payout ratio (DPR) is 34.93%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.